Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer

Sunitinib has been registered for the treatment of advanced renal cell cancer (RCC). As patient inclusion was highly selective in previous studies, experience with sunitinib in general oncological practice remains to be reported. We determined the efficacy and safety of sunitinib in patients with ad...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Veldt, A A M, Boven, E, Helgason, H H, van Wouwe, M, Berkhof, J, de Gast, G, Mallo, H, Tillier, C N, van den Eertwegh, A J M, Haanen, J B A G
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2480961/
https://www.ncbi.nlm.nih.gov/pubmed/18594533
http://dx.doi.org/10.1038/sj.bjc.6604456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2480961/
https://www.ncbi.nlm.nih.gov/pubmed/18594533
http://dx.doi.org/10.1038/sj.bjc.6604456

Ejemplares similares